vs

Side-by-side financial comparison of ASP Isotopes Inc. (ASPI) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $16.7M, roughly 1.9× ASP Isotopes Inc.). On growth, ASP Isotopes Inc. posted the faster year-over-year revenue change (1295.7% vs -0.2%). OptimizeRx Corp produced more free cash flow last quarter ($7.1M vs $-47.4M).

ASP Isotopes Inc. is a specialty materials firm focused on developing and producing high-purity custom isotopes. Its products serve key sectors including nuclear medicine, targeted cancer therapies, advanced energy, and industrial research, with customers across North America, Europe and Asia Pacific.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

ASPI vs OPRX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.9× larger
OPRX
$32.2M
$16.7M
ASPI
Growing faster (revenue YoY)
ASPI
ASPI
+1295.9% gap
ASPI
1295.7%
-0.2%
OPRX
More free cash flow
OPRX
OPRX
$54.5M more FCF
OPRX
$7.1M
$-47.4M
ASPI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASPI
ASPI
OPRX
OPRX
Revenue
$16.7M
$32.2M
Net Profit
$5.0M
Gross Margin
12.5%
74.8%
Operating Margin
26.6%
Net Margin
15.6%
Revenue YoY
1295.7%
-0.2%
Net Profit YoY
-586.8%
6535.9%
EPS (diluted)
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPI
ASPI
OPRX
OPRX
Q4 25
$16.7M
$32.2M
Q3 25
$4.9M
$26.1M
Q2 25
$29.2M
Q1 25
$21.9M
Q4 24
$32.3M
Q3 24
$21.3M
Q2 24
$18.8M
Q1 24
$19.7M
Net Profit
ASPI
ASPI
OPRX
OPRX
Q4 25
$5.0M
Q3 25
$-12.9M
$779.0K
Q2 25
$1.5M
Q1 25
$-2.2M
Q4 24
$-78.0K
Q3 24
$-9.1M
Q2 24
$-4.0M
Q1 24
$-6.9M
Gross Margin
ASPI
ASPI
OPRX
OPRX
Q4 25
12.5%
74.8%
Q3 25
8.7%
67.2%
Q2 25
63.8%
Q1 25
60.9%
Q4 24
68.1%
Q3 24
63.1%
Q2 24
62.2%
Q1 24
62.0%
Operating Margin
ASPI
ASPI
OPRX
OPRX
Q4 25
26.6%
Q3 25
-306.1%
7.9%
Q2 25
10.9%
Q1 25
-9.6%
Q4 24
11.2%
Q3 24
-40.2%
Q2 24
-19.9%
Q1 24
-25.5%
Net Margin
ASPI
ASPI
OPRX
OPRX
Q4 25
15.6%
Q3 25
-263.7%
3.0%
Q2 25
5.2%
Q1 25
-10.0%
Q4 24
-0.2%
Q3 24
-42.8%
Q2 24
-21.3%
Q1 24
-35.0%
EPS (diluted)
ASPI
ASPI
OPRX
OPRX
Q4 25
$0.27
Q3 25
$-0.15
$0.04
Q2 25
$0.08
Q1 25
$-0.12
Q4 24
$0.00
Q3 24
$-0.50
Q2 24
$-0.22
Q1 24
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPI
ASPI
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$333.3M
$23.4M
Total DebtLower is stronger
$14.4M
$26.3M
Stockholders' EquityBook value
$204.2M
$128.3M
Total Assets
$498.0M
$176.9M
Debt / EquityLower = less leverage
0.07×
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPI
ASPI
OPRX
OPRX
Q4 25
$333.3M
$23.4M
Q3 25
$113.9M
$19.5M
Q2 25
$16.6M
Q1 25
$16.6M
Q4 24
$13.4M
Q3 24
$16.1M
Q2 24
Q1 24
Total Debt
ASPI
ASPI
OPRX
OPRX
Q4 25
$14.4M
$26.3M
Q3 25
$13.9M
$28.8M
Q2 25
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Q1 24
$37.8M
Stockholders' Equity
ASPI
ASPI
OPRX
OPRX
Q4 25
$204.2M
$128.3M
Q3 25
$74.1M
$122.3M
Q2 25
$119.3M
Q1 25
$116.3M
Q4 24
$117.0M
Q3 24
$114.5M
Q2 24
$121.0M
Q1 24
$122.5M
Total Assets
ASPI
ASPI
OPRX
OPRX
Q4 25
$498.0M
$176.9M
Q3 25
$225.9M
$170.3M
Q2 25
$169.3M
Q1 25
$167.8M
Q4 24
$171.2M
Q3 24
$165.2M
Q2 24
$172.9M
Q1 24
$176.4M
Debt / Equity
ASPI
ASPI
OPRX
OPRX
Q4 25
0.07×
0.20×
Q3 25
0.19×
0.24×
Q2 25
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPI
ASPI
OPRX
OPRX
Operating Cash FlowLast quarter
$-37.8M
$7.1M
Free Cash FlowOCF − Capex
$-47.4M
$7.1M
FCF MarginFCF / Revenue
-284.7%
22.0%
Capex IntensityCapex / Revenue
57.9%
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPI
ASPI
OPRX
OPRX
Q4 25
$-37.8M
$7.1M
Q3 25
$-8.9M
$3.2M
Q2 25
$4.6M
Q1 25
$3.9M
Q4 24
$198.0K
Q3 24
$1.8M
Q2 24
$782.0K
Q1 24
$2.1M
Free Cash Flow
ASPI
ASPI
OPRX
OPRX
Q4 25
$-47.4M
$7.1M
Q3 25
$-12.0M
$3.2M
Q2 25
$4.6M
Q1 25
$3.8M
Q4 24
$181.0K
Q3 24
$1.8M
Q2 24
$737.0K
Q1 24
$2.1M
FCF Margin
ASPI
ASPI
OPRX
OPRX
Q4 25
-284.7%
22.0%
Q3 25
-245.5%
12.2%
Q2 25
15.6%
Q1 25
17.5%
Q4 24
0.6%
Q3 24
8.3%
Q2 24
3.9%
Q1 24
10.6%
Capex Intensity
ASPI
ASPI
OPRX
OPRX
Q4 25
57.9%
0.0%
Q3 25
64.4%
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.1%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
ASPI
ASPI
OPRX
OPRX
Q4 25
1.41×
Q3 25
4.11×
Q2 25
2.98×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons